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Abstract
Purpose To understand the mechanisms behind platinum
drug/DENSPM-induced inhibition of cancer cell growth,
we compared the effects of oxaliplatin and cisplatin when
combined with DENSPM on the induction of SSAT
mRNA, activity, polyamines and cell growth in A2780
human ovarian carcinoma cells and their oxaliplatin- and
cisplatin-resistant variants A2780/C10B and A2780/CP,
respectively.
Methods Parental and Pt-resistant cells were treated with
platinum agent alone, DENSPM alone or combination
(10 lM each, 20 h). QRT–PCR, radioactive product mea-
surement and HPLC were used for mRNA, activity and
polyamine pools, respectively; drug interaction on cell
growth was by SRB and isobologram analysis.
Results Both platinum agents induced SSAT mRNA in
parental A2780 cells, but not in resistant cells. Platinum
drug/DENSPM combinations produced high levels of
SSAT activity in parental cells with signiﬁcant depletion of
spermine and spermidine, but not in resistant cells. Co-
treatment with platinum agents increased the levels of
DENSPM in all cell lines. Oxaliplatin/DENSPM combi-
nation was superior to cisplatin/DENSPM in the inhibition
of cell growth in parental cells. No synergy was observed
in the resistant cells.
Conclusions Increased DENSPM levels following
co-treatment with Pt agents enhances the translation and
stability of SSAT protein leading to polyamine pool
depletion, facilitating more Pt–DNA adduct formation in
parental cells. Oxaliplatin/DENSPM combination is supe-
rior to cisplatin/DENSPM in cell growth inhibition as
DACH-Pt DNA adducts are cytotoxic even at relatively
fewer numbers. Reduced platinum uptake in Pt-resistant
cells contributes to reduced SSAT mRNA induction and
absence of synergy when combined with DENSPM.
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Introduction
Platinum (Pt) drugs cisplatin and oxaliplatin play a central
role in cancer chemotherapy. The prototype drug cisplatin
is used in ovarian, testicular, bladder, small cell lung and
head and neck cancers among many others. Oxaliplatin
while active in some of the above cancers is uniquely
active in colon carcinoma when administered in combi-
nation with 5-ﬂuorouracil and has been approved for
clinical use for this indication. It is widely believed that
Pt–DNA adduct formation is the key lesion for the activity
of these agents preventing DNA replication and transcrip-
tion and the resulting DNA damage itself inducing down-
stream signaling leading to apoptotic cell death [45].
However, all platinum drugs also bind to RNA and protein
within the cell and these interactions may also play a role
in their mechanism of action. Mechanisms of resistance to
platinum agents are multifactorial including impaired drug
accumulation, inactivation by thiols, enhanced DNA repair,
replicative bypass, tolerance to damage and altered down-
stream signaling [17, 36, 37, 39].
Microarray studies on oxaliplatin- [4, 42] or cisplatin
[42]-treated cells have suggested that platinum drugs can
affect the expression of genes in many other pathways and
identiﬁedspermidine/spermineN
1acetyltransferase(SSAT)
akeypolyaminecatabolicpathwayenzymeasaprominently
up-regulated gene. Other microarray studies have identiﬁed
SSAT up-regulation by oxaliplatin in HCT-116 colon
carcinomacells[1,4]andMCF-7cellsandby5-ﬂuorouracil
(5-FU) in HCT-116 cells [1, 47] and MCF-7 cells [31]. Our
own gene expression proﬁling studies of oxaliplatin- or
cisplatin-treated A2780 ovarian carcinoma cells indicated
that both drugs not only up-regulate SSAT gene expression
but they also down-regulate the polyamine biosynthetic
pathway enzymes ornithine decarboxylase (ODC) and
S-adenosylmethionine decarboxylase (SAMDC) [42]. We
and others have found that oxaliplatin up-regulated SSAT
expressionisnottranslatedintoproteinand/oractivitytoany
signiﬁcant extent [1, 23, 24]; but when combined with the
polyamine analog N
1,N
11diethylnorspermine (DENSPM), a
synergistic induction of both SSAT mRNA [1, 23, 24],
protein[1]andactivityoccurs[23,24].Thisisnotsurprising
becausebothSSAT mRNA and protein have short half-lives
and polyamine analogs have been shown to facilitate
increased transcription and the stability of the transcript [7]
as well as increase the translation and stability of the SSAT
protein [7].
Polyamines, small cationic molecules which are essen-
tial for cell proliferation and survival, are a well-recog-
nized therapeutic target. SSAT is the key enzyme in
polyamine catabolism and its induction leads to inhibition
of cell growth and apoptosis [9, 25]. Because polyamine
levels and metabolic rates are higher in tumor than in
normal cells [34], drugs have been designed to either up-
regulate polyamine catabolism or down-regulate their
biosynthesis. The clinically tested polyamine analog
DENSPM targets the polyamine pathway by up-regulating
catabolism via SSAT induction and decreasing their bio-
synthesis via down-regulation of the biosynthetic enzymes
ODC and SAMDC [41]. DENSPM has been tested in Phase
I and Phase II clinical trials [11, 19, 40, 46], but with no
demonstrated single agent activity. A few studies, includ-
ing our own, have shown that oxaliplatin and DENSPM
combination synergistically up-regulates the expression of
SSAT in A2780 [23] and HCT-116 cells [1, 10, 24] with
concurrent decline in polyamine pools [10, 23, 24]. Others
have shown that DENSPM combined with paclitaxel or
5-FU produces a synergistic induction of SSAT mRNA and
activity in MDA-MB-231 cells [33]. The synergistic
induction of SSAT protein and activity by oxaliplatin/
DENSPM combinations in HCT-116 and other colon car-
cinoma cell lines and A2780 ovarian carcinoma cells result
in synergistic cell kill [1, 24] or enhancement of oxaliplatin
cytotoxicity [23]. While exhibiting lower levels of synergy
in SSAT induction after oxaliplatin/DENSPM combina-
tion, the oxaliplatin-resistant HCT-116 cells showed an
enhanced cell death following treatment with this drug [1].
In addition, siRNA-mediated down-regulation of SSAT
resulted in decreased cell kill [1]. Cisplatin, DENSPM
combinations have been shown to produce synergistic cell
death in MDA-MB-231 breast cancer cells [33]. Mareverti
et al., have shown that another polyamine analog N
1,
N
12-bis(ethyl)spermine (BESPM) induced SSAT at much
lower levels in cisplatin-resistant C13* ovarian carcinoma
cells than the parental cells but the combinations of
cisplatin and BESPM still produced synergistic cell kill
[29]. All these lines of evidence suggest SSAT induction to
be a potential therapeutic target in cancer chemotherapy.
While recent studies focused on combining the clinically
relevant DENSPM with oxaliplatin, detailed studies of
cisplatin combinations with DENSPM on polyamine
pathway and growth are lacking in ovarian cancer cells.
The aim of the present work has been to conduct a
simultaneous comparison of the interactions of DENSPM
with cisplatin and oxaliplatin under identical conditions at
the level of SSAT mRNA, activity, polyamine pools and
the effect of the combination on inhibition of cell growth in
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123A2780 ovarian carcinoma cells and their corresponding
oxaliplatin and cisplatin-resistant variants A2780/C10B
and A2780/CP, respectively. The mechanisms of resistance
for both A2780/CP and A2780/C10B have been described
previously and include decreased drug accumulation and
increased glutathione for both cell lines and in addition
increased repair of DNA damage in cisplatin-resistant
A2780/CP [21, 22].
Materials and methods
Drugs
Oxaliplatin was a gift from Dr. Paul Juniewicz of Sanoﬁ-
Synthelabo (Malvern, PA). Cisplatin was purchased from
Sigma–Aldrich (St. Louis, MO). DENSPM was generously
provided by Dr. Ronald Merriman from Pﬁzer Pharma-
ceuticals (Ann Arbor, MI).
Cell culture
All cell lines were of human origin and mycoplasma-free.
The ovarian carcinoma cell line A2780 and its cisplatin-
resistant variant A2780/CP were a gift from Dr. Ozols (Fox
Chase Cancer Center, Philadelphia, PA). The oxaliplatin-
resistant A2780/C10B subline was derived in our labora-
tory as a single cell clone from the previously described
stably oxaliplatin-resistant A2780/C10 cell line using limit-
dilution procedure [22, 43]. Both A2780/CP and A2780/
C10B variants are stably resistant when maintained
in drug-free medium. All cell lines were maintained in
RPMI 1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen, Grand Island, NY) and 1%
L-Glutamine (Invitrogen, Grand Island, NY).
Cell growth inhibition
Cells were plated in a 96-well plate (1 9 10
3 cells/well) on
day 0 followed by exposure to oxaliplatin or cisplatin on
day 1. Cells were exposed to drug concentrations ranging
from 0.1 to 100 lM for 72 h, after which the cells were
ﬁxed and subjected to the sulforhodamine-B micro-culture
colorimetric assay (SRB) [38]. Percent survival was
determined as (OD570 (treated cells)/OD570 (untreated
cells)) 9 100.
Drug treatment conditions for measurement of SSAT
gene expression, SSAT enzyme activity and polyamine
pools
Cells were treated concurrently with either of the platinum
agents (10 lM) and DENSPM (10 lM) for 20 h, washed
thoroughlywithPBS,andincubatedforanother24 hindrug-
free medium prior to harvesting the cells. Single agent
treatments were performed under identical exposure and
incubation conditions. The concentrations chosen for all the
drugs are clinically achievable [18, 19, 26] and the drug
exposure time reﬂects the half-life observed for oxaliplatin
[18].Inaddition,combiningDENSPMwithoxaliplatinunder
these conditions produced synergistic increases in SSAT
mRNAandactivityinA2780cells[23]andinHCT-116cells
[24]. The same exposure time was chosen for cisplatin to
provide a comparative characterization with oxaliplatin. The
post-drug treatment incubation of 24 h in drug-free medium
was chosen based on our previous studies [42] which showed
that SSAT gene expression increases with time up to 24 h
after the end of platinum drug exposure. Control cells were
incubated identically in the absence of drug.
Real time quantitative RT-PCR
SSAT mRNA levels were measured by real-time quanti-
tative RT-PCR (Taqman assay) using PE-ABI 7900
Sequence Detection System as described before [24]. The
mRNA level is expressed relative to the endogenous
standard (b-actin) measured concurrently from the same
RNA extracts and the cDNA preparations. The drug
untreated control is the calibrator in these assays and fold
induction relative to the calibrator is presented.
SSAT activity measurements
SSAT activity assay was performed as described previ-
ously [35]. In brief, the reaction mixture contained [
14C]
acetylCoA (60 mCi/mmol, NEN Radiochemicals, Wal-
tham, MA) spermidine and cell extract in Tris HCl buffer,
pH 7.5. The [
14C]acetylated spermidine product generated
by the enzyme reaction is captured on discs followed by
counting of radioactivity. Protein in the cell lysate was
determined by the Bradford assay [5]. The activity reported
is pmol/min/mg protein.
Polyamine pools
Intracellular polyamine pools and acetylated polyamine
pools were extracted with 0.6 N perchloric acid, dansylated
and analyzed using reverse phase HPLC with ﬂuorescence
detection as previously described [44]. Polyamine pools are
expressed as pmol/mg protein.
Drug interaction on cell growth inhibition
The effect of two drug combination on cell growth was
examined as described by Faessel et al. [13]. Exponentially
growing A2780, A2780/C10B and A2780/CP cell lines
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123were seeded in 96-well microtiter plates in drug-free media
and incubated for 24 h. Treatment with oxaliplatin or cis-
platin, and the combination of each of the platinum drugs
and DENSPM was then carried out in ﬁxed binary ratio
mixtures (1:4, 1:2, 1:1, 2:1, 4:1) of each drug at their IC50
concentrations in each of the cell lines. Each experiment
consisted of 5 plates and each plate included 12 wells each
for control, oxaliplatin, DENSPM and each of the 5 com-
binations of oxaliplatin and DENSPM in constant ratio
with 12 dilutions. The serial dilutions were randomized as
described earlier [12, 13]. Following 96 h of drug expo-
sure, the cells were ﬁxed, stained with sulforhodamine-B
(SRB), washed thoroughly to remove the excess dye
and absorbance read at 570 nm and inhibition of cell
growth was determined. The data were de-randomized
and analyzed. Experiments for each cell line were repeated
2–4 times, such that the data analyzed were obtained from
10 to 20 separate plates.
Modeling of the oxaliplatin/DENSPM interaction
on cell growth inhibition
To assess the nature (synergy, additivity or antagonism)
and intensity of the binary agent interactions in the com-
bination growth inhibition studies, a simple approach
adapted from work by Gessner [16] was used. The Hill
model (below) is ﬁt to each set of single agent data and
each set of ﬁxed-ratio combination concentration-effect
data.
E ¼ B þ
Econ   B ðÞ C
IC50
 m
1 þ C
IC50
 m
In this equation, E is the measured effect (absorbance)
and C is dose of drug. The four estimable parameters are
Econ, the effect at zero concentration; B, the asymptotic
effect at inﬁnite drug concentration; IC50, the median
effective dose of drug; and m, a slope/sigmoidicity
parameter. The Hill equation was ﬁt to data with
WinNonlin Pro., Version 5.2 with nonlinear regression
using the Gauss–Newton Minimization Method, with the
estimation of the four parameters. The goodness-of-ﬁt of
the pharmacodynamic (PD) model to the cell inhibition
data was assessed using a combination of the following
criteria: the Akaike Information Criterion, sum of weighted
squared residuals, percent coefﬁcient of variation (%CV)
of the estimated PD parameters, visual inspection of the
predicted and observed concentration-effect proﬁles and
residual (difference between observed and predicted) plots.
A uniform weighting scheme was used for the analysis.
Isobol graphs are then made from these data, at the IC10,
IC25,I C 50,I C 75 and IC90 levels, using SAS Version 8.2.
Bowing of the isobols toward the Southwest corner of the
graph indicates synergy; whereas bowing of the isobols
toward the Northeast corner of the graph indicates
antagonism; and when the isobols follow the diagonal
additivity line, additivity is indicated.
Statistical analysis
Differences in cellular mRNA levels, enzyme activity and
polyamine pools before and after drug treatments were
evaluated using Student’s t test (Systat Software Inc.,
Richmond,CA).PvaluesB0.05wereconsideredsigniﬁcant.
Results
Cytotoxicity proﬁles of the platinum-resistant cells
The cytotoxicity proﬁles of oxaliplatin in A2780/C10B
compared to the parental A2780 cells is shown in Fig. 1a.
Compared to the parental A2780 cells, the A2780/C10B
subline is 15-fold resistant to oxaliplatin; IC50 concentra-
tions of A2780 and A2780/C10B are 0.2 and 3.0 lM,
respectively. In Fig. 1b is shown the cytotoxicity proﬁle for
cisplatin in A2780 and the cisplatin-resistant variant
A2780/CP. Compared to the parental cells, the A2780/CP
cells are *12 fold resistant to cisplatin; IC50 concentra-
tions for cisplatin in A2780 and A2780/CP are 0.54 and
6.58 lM, respectively.
SSAT induction and polyamine pools
The SSAT mRNA, activity and polyamine pools were
measured in the parental A2780 and the oxaliplatin-resis-
tant A2780/C10B and the cisplatin-resistant A2780/CP
cells. For these experiments, the cells were treated with
each of the platinum agents or DENSPM (10 lM each)
singly and in combination for 20 h followed by a 24-h
incubation in drug-free medium. The rationale for choosing
these conditions is presented in ‘‘Materials and methods’’.
As seen in Fig. 2a, b, both platinum agents induced SSAT
mRNA in A2780 cells, better than DENSPM in this cell
line, oxaliplain producing a 61-fold increase and cisplatin a
42-fold increase relative to the no-drug controls. DENSPM
treatment resulted in a small increase in SSAT mRNA
(*16-fold) as we have noted also before for this cell line
[23]. The differences between oxaliplatin and DENSPM
are signiﬁcant (P = 0.028). When combined with DENS-
PM, both oxaliplatin and cisplatin induced a signiﬁ-
cant further increase in SSAT mRNA in the parental
A2780 cells; oxaliplatin/DENSPM combination produced a
*96-fold induction, while cisplatin/DENSPM produced a
69-fold induction. While this induction for the combination
is signiﬁcant for both platinum agents in comparison with
404 Cancer Chemother Pharmacol (2011) 67:401–414
123DENSPM (P\0.05), it was not signiﬁcant in comparison
with platinum agent alone. Unlike the parental cells, the
SSAT mRNA induction is signiﬁcantly curtailed both in
the oxaliplatin-resistant A2780/C10B cells and in the cis-
platin-resistant A2780/CP cells. In comparison with the
single agents, the drug combination produced a slight but
not signiﬁcant increase in SSAT mRNA in both resistant
cell lines. The differences in mRNA induction between the
parental and the resistant cells with single agent treatments
as well as after combining the platinum agent with
DENSPM are signiﬁcant (P\0.05). From these data, it
is evident that acquired resistance to either platinum
drug hinders the induction of SSAT mRNA both after
single agent platinum treatment and in combination with
DENSPM.
Although both platinum agents produced a signiﬁcant
increase in SSAT mRNA in A2780 cells it did not translate
into a proportional increase in SSAT activity (Fig. 3a, b).
Thus, oxaliplatin treatment produced a *4-fold increase in
SSAT activity and a 2-fold increase after cisplatin relative
to the corresponding no-drug controls in A2780 cells
(P\0.01 for both). A highly synergistic increase in SSAT
activity occurred in these cells when each of the platinum
agents was combined with DENSPM (P\0.001), far
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Fig. 1 a Comparative dose–response curves for oxaliplatin in A2780
ovarian carcinoma and the oxaliplain-resistant A2780/C10B cells
following a 72-h continuous exposure to oxaliplatin. b Comparative
dose–response curves for cisplatin in A2780 ovarian carcinoma cells
and the cisplatin-resistant A2780/CP cells following a 72-h contin-
uous exposure to cisplatin. Data represent mean ± SE where n = 3.
The IC50 for oxaliplatin in A2780 and A2780/C10B are 0.2 and
3.0 lM, respectively. The IC50 for cisplatin in A2780 and A2780/CP
are 0.54 and 6.58 lM, respectively
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Fig. 2 a Effect of oxaliplatin alone, DENSPM alone or oxaliplatin/
DENSPM combination on SSAT mRNA in A2780 and A2780/C10B
cells. b Effect of cisplatin alone, DENSPM alone or cisplatin/
DENSPM combination on SSAT mRNA in A2780 and A2780/CP
cells. Cells were exposed to 10 lM platinum agent or 10 lM
DENSPM singly, or in combination for 20 h followed by another 24-h
incubation in drug-free medium prior to SSAT mRNA measurements.
Data shown are fold induction relative to drug untreated controls.
Data represent mean ± SE where n = 2–5 separate cell pellets in up
to 3 separate experiments. In a, the fold-induction in A2780 after
oxaliplatin, DENSPM and oxaliplatin/DENSPM are 60.6 ± 12.3,
15.8 ± 7.8 and 95.5 ± 15, respectively; the fold induction in A2780/
C10B cells after the same treatments are 2.8 ± 0.1, 2.3 ± 0.4, and
7.4 ± 1.3, respectively. In b, the fold-induction in A2780 cells after
cisplatin, DENSPM and cisplatin/DENSPM are 42.3 ± 1.1,
15.8 ± 7.8 and 69.0 ± 20.2, respectively; the fold induction in
A2780/CP cells after the same treatments are 3.5 ± 1.3, 3.7 ± 1.9
and 5.9 ± 0.6, respectively
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123superior than any of the single agents. Under identical
conditions of treatment oxaliplatin/DENSPM combination
produced an average 400-fold increase in SSAT activity
and cisplatin/DENSPM combination an average 245-fold
increase; the differences between the two platinum agents
were not statistically signiﬁcant. Unlike the parental cells,
the induction of SSAT activity with oxaliplatin/DENSPM
is completely curtailed in the oxaliplatin-resistant A2780/
C10B cells showing *1% activity relative to the parental
A2780 cells. The induction of SSAT activity observed in
A2780/CP cells was\10% of that seen in A2780 cells. The
differences between parental and resistant cells in inducing
SSAT activity are highly signiﬁcant for both oxaliplatin
and cisplatin when combined with DENSPM (P = 0.016 to
\0.001).
Polyamine pools were measured after treatment with
oxaliplatin alone, DENSPM alone or a combination of the
two under identical conditions as for SSAT mRNA and
activity in the parental A2780 (Fig. 4a) and A2780/C10B
(Fig. 4b) cells. Polyamine pools were also measured after
treatment with cisplatin alone, DENSPM alone or a com-
bination of cisplatin and DENSPM in A2780 (Fig. 4c) and
the cisplatin-resistant A2780/CP (Fig. 4d) cells. Changes in
putrescine (PUT), spermidine (SPD) and spermine (SPM)
levels and that of N
1acetylspermidine (N
1AcSpd) levels
under each of the treatment conditions relative to the
untreated control are shown in Fig. 4a–d. DENSPM levels
in cells were also measured. As evident from the data in
both parental and platinum-resistant cells (A2780/C10B
and A2780/CP), putrescine levels showed a tendency to
increase with the drug treatment especially when the
platinum drug and DENSPM were combined, while sper-
midine and spermine levels declined with the combination
in all cells. The increases in putrescine, after oxaliplatin
alone or when combined with DENSPM, were signiﬁcant
in both A2780 and A2780/C10B cells (P\0.05 for all).
The increases in putrescine after cisplatin alone or when
combined with DENSPM, were signiﬁcant only in A2780/
CP cells (P\0.05). As seen in Fig. 4a–d, the declines in
spermidine and spermine pools produced by the platinum
agent/DENSPM combinations in oxaliplatin-resistant
A2780/C10B cells and the cisplatin-resistant A2780/CP
cells are signiﬁcantly lower than those observed in parental
A2780 cells. The oxaliplatin/DENSPM combination pro-
duced 83 and 80% decline in spermidine and spermine,
respectively in A2780 cells (Fig. 4a); similarly, the cis-
platin/DENSPM combination produced 84% decline in
spermidine but only 70% decline in spermine in parental
cells (Fig. 4c), all declines being highly statistically sig-
niﬁcant for both platinum agents (P\0.001). In A2780/
C10B cells, the oxaliplatin/DENSPM combination pro-
duced a 30% decline in spermidine and 74% decline in
spermine. The cisplatin/DENSPM treatment produced a
decline of only 49% in spermidine and 47% of spermine in
A2780/CP cells. Putrescine levels were found to be rela-
tively higher in the cisplatin-resistant A2780/CP cells
compared to the parental A2780 or A2780/C10B cells. The
signiﬁcance of this is unclear at this time.
A signiﬁcant point of interest is that while spermi-
dine and spermine levels declined in A2780 cells after
DENSPM combinations with both platinum agents,
the N
1acetylspermidine (N
1AcSpd) levels were measur-
able only after oxaliplatin and oxaliplatin/DENSPM
combinations. The oxaliplatin/DENSPM combination
produced signiﬁcantly higher levels of N
1AcSpd com-
pared to oxaliplatin alone in these cells (P\0.001).
There were relatively small but measurable levels of
N
1AcSpd also in A2780/C10B but only in oxaliplatin/
DESNPM-treated cells. Normally found in low or below
detectable levels in un-induced cells, accumulation of
intracellular acetylated polyamines is the best indicator
of SSAT induction.
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Fig. 3 a Effect of oxaliplatin alone, DENSPM alone or oxaliplatin/
DENSPM combination on SSAT activity in A2780 and A2780/C10B
cells. b Effect of cisplatin alone, DENSPM alone or cisplatin/
DENSPM combination on SSAT activity in A2780 and A2780/C10B
cells. Data shown are SSAT activity in pmol/min/mg protein. Data
represent mean ± SE where n = 3–9 separate cell pellets in up to 3
separate experiments. In a, SSAT activity in A2780 for control (no-
drug treatment) cells, and in cells treated with oxaliplatin, DENSPM
and oxaliplatin/DENSPM were 15.0 ± 1.1, 57.3 ± 11.7, 53.9 ± 28.7
and 6130.2 ± 1182.0 pmol/min/mg protein, respectively; the same
for A2780/C10B cells were 11.0 ± 3.0; 24.7 ± 3.8, 25.7 ± 1.8;
46.7 ± 0.9 pmol/min/mg protein, respectively. In b, SSAT activity in
A2780 for control cells and in cells treated with cisplatin, DENSPM
and cisplatin/DENSPM were 23.7 ± 1.7, 52.6 ± 12.5, 272.2 ± 30.1
and 5807 ± 1218 pmol/min/mg protein, respectively; the same for
A2780/CP cells were 20.9 ± 5.5, 33.4 ± 8.1, 165.2 ± 18.7,
533 ± 76.9 pmol/min/mg protein, respectively
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123The polyamine analog DENSPM was also measured in
these experiments. In both parental and drug-resistant cells,
under identical conditions, the DENSPM levels were
higher in all cell lines when the treatment was in combi-
nation with the platinum agent. An approximate 200%
increase was seen in DENSPM levels in A2780 cells when
administered with either oxaliplatin or cisplatin (P\0.001
for both). An approximate 150% increase in DENSPM
was seen in A2780/CP cells after cisplatin/DENSPM
(P = 0.003) and 140% increase in A2780/C10B cells after
oxaliplatin/DENSPM, the later not statistically signiﬁcant.
Cytotoxicity interactions between platinum agent
and DENSPM
N
1acetylspermidine was detected only after oxaliplatin/
DENSPM combination and not in cisplatin/DENSPM
combinations. Likewise, the degree of SSAT activity
induction by platinum agent/DENSPM combination dif-
fered markedly between sensitive and resistant cell lines.
Therefore, we performed drug interaction analysis on cell
growth using a wide range of concentrations and combi-
nation treatments of each of the platinum agents and
DENSPM in A2780, A2780/C10B and A2780/CP cells.
We hypothesized that SSAT induction was a determinant
of the cytotoxic response to the drug combination. At all
concentrations and ratios of oxaliplatin/DENSPM combi-
nation, the two drugs synergized to produce increased
growth inhibition in A2780 parental cells (Fig. 5a). In
contrast to combination with oxaliplatin, DENSPM com-
binations with cisplatin in A2780 cells were observed to
display limited synergy in producing cell growth inhibition
at low drug concentrations, which was reduced as the drug
concentrations increased; a shift toward antagonism was
evident at high concentrations (Fig. 5b). As opposed to the
parental A2780 cells in A2780/C10B cells, the drug com-
bination produced an antagonistic response and only a
limited synergy at the highest doses and only in certain
ratios (Fig. 5c). Cisplatin/DENSPM exhibited an antago-
nistic response at all concentrations at majority of the drug
ratios in A2780/CP cells (Fig. 5d).
Discussion
The polyamine analog DENSPM is a proven inducer of
SSAT in many cell types and has also been shown to down-
regulate the key biosynthetic pathway enzymes ODC and
SAMDC. Induction of SSAT activity and depletion of
polyamine pools especially that of spermidine have been
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Fig. 4 Effect of oxaliplatin alone, DENSPM alone or oxaliplatin/
DENSPM combination on polyamine pools in A2780 (a) and A2780/
C10B (b) cells and cisplatin alone, DENSPM alone or cisplatin/
DENSPM on polyamine pools in A2780 (c) and A2780/CP (d) cells.
Data shown are pmoles/mg protein. Note that N
1 acetyl spermidine
was detected only in oxaliplatin/DENSPM combinations. DENSPM
levels in cells when administered alone or in combination with the
platinum agent is also presented for all the cell lines. Note that
DENSPM levels are higher when administered with the platinum
agent. Data represent mean ± SE where n = 3–9 separate cell pellets
in up to 3 separate experiments
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123shown to be related to inhibition of cancer cell growth
[8, 27, 35, 44]. Therefore, this agent has great potential as a
means of targeting the polyamine pathway as a mechanism
to kill cancer cells and has accordingly been tested clini-
cally [11, 19, 40, 46]. While this drug showed no single
agent activity in the clinic, combination studies have yet to
be reported. Several in vitro studies of synergistic cell
growth inhibition of DENSPM combinations with various
chemotherapeutic agents such as oxaliplatin [1, 24] and
5-ﬂuorouracil [1] in colon carcinoma cell model, paclitaxel
[33] and to a limited extent of cisplatin [33] in breast
cancer cell models have been reported. Cisplatin is rou-
tinely used in ovarian cancer therapy and oxaliplatin has
activity in this indication. Due to the importance of plati-
num agents in the treatment of this malignancy, it is
imperative that we gain a better understanding of platinum
agent/DENSPM combinations in ovarian cancer models
and how this may eventually be brought to the clinical
setting to improve treatment. While we noted from our
earlier microarray studies that both platinum drugs impact
on the polyamine pathway in A2780 ovarian carcinoma
cells [42] and that oxaliplatin/DENSPM combinations
synergize to produce high SSAT activity and lowered
polyamines with enhancement of oxaliplatin cytotoxicity
[23], a comparison of oxaliplatin and cisplatin with
DENSPM combinations in the context of SSAT activity,
polyamine pools and inhibition of cell growth has not been
performed. To our knowledge, there were also no published
reports on how cisplatin or oxaliplatin resistance may
affect or modulate SSAT activity, polyamine pools and cell
Fig. 5 a Isobolograms of
oxaliplatin and DENSPM in
combination treatment of
A2780 cells. b Isobolograms of
cisplatin and DENSPM in
combination treatment of
A2780 cells. c Isobolograms of
oxaliplatin and DENSPM in
combination treatment of
A2780/C10B cells.
d Isobolograms of cisplatin and
DENSPM in combination
treatment of A2780/CP cells. In
the axis legend, ‘9’ refers to the
IC concentrations for each drug.
The diagonal dashed line
represents additivity and data
below this line implies
synergism and data above
represent antagonism
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123growth when platinum agents are combined with DENSPM
in comparison with the parental cells in ovarian carcinoma
cells.
We show here for the ﬁrst time that when tested con-
currently at a variety of concentrations and combinations
with DENSPM, oxaliplatin synergizes with DENSPM in
inhibiting cell growth better than cisplatin in this ovarian
cancer cell model. It is intriguing why this is the case,
as both agents produced high levels of SSAT activity
and polyamine pool depletion when combined with
DENSPM. It should, however, be emphasized that
N
1acetylspermidine considered a good indicator of SSAT
activity was detectable only in oxaliplatin/DENSPM
combinations. Further, the measured fold increases in
SSAT activity levels were higher and both spermine and
spermidine were depleted highly in oxaliplatin/DENSPM
combinations. In the current study, we observed that
platinum agent/DENSPM combinations not only induced
highly signiﬁcant depletion of spermidine and spermine
levels, but also a signiﬁcant increase in putrescine levels.
Whether this is due to back conversion of acetylated
spermidine or increase in ornithine decarboxylase activity
is unclear at this time.
We previously demonstrated that both oxaliplatin and
cisplatin up-regulate spermine oxidase (SMO) and poly-
amine oxidase (PAO) in a concentration-dependent fashion
Fig. 5 continued
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123in A2780 cells [23]. Synergy between oxaliplatin and
DENSPM was apparent for SMO up-regulation but not for
PAO in A2780 cells [23]. We also demonstrated that ox-
aliplatin/DENSPM induced both mRNA and higher protein
levels for SMO in human colon carcinoma HCT-116 cells
[24]. Spermine oxidase (SMO) oxidizes spermine directly
to spermidine; PAO preferentially oxidizes N
1acetylated
polyamines to convert acetylated spermine and spermidine
to spermidine and putrescine, respectively [6]. Oxidation of
spermine to spermidine by SMO produces reactive oxygen
species (ROS) down-stream to H2O2 generated as a reac-
tion product [6]. Thus, one cannot rule out the possibility
that additional factors such as increased production of
highly cytotoxic ROS through SMO reaction may have
contributed to the increased cytotoxicity of oxaliplatin/
DENSPM.
Previous studies have shown synergism between oxa-
liplatin/DENSPM combinations on cell death in HCT-116
colon carcinoma cells resistant to oxaliplatin [1] and that
for cisplatin and another polyamine analog BESPM in
2008 ovarian carcinoma cells resistant to cisplatin [29].
The detailed studies presented here exploring a variety of
concentrations and ratios of the two drugs indicate that
resistance to either oxaliplatin or cisplatin curtails the
induction of SSAT, polyamine pool depletion and cell
growth inhibition in A2780 cells. Thus, studies presented
Fig. 5 continued
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123here comparing the parental with both the oxaliplatin-
resistant and cisplatin-resistant cells indicate that the SSAT
induction and polyamine pool depletion play a signiﬁcant
role in cell growth inhibition.
While the mechanisms of the platinum drug-polyamine
interactions are not completely understood, based on the
mechanism of action of polyamine analogs with respect to
SSAT mRNA and protein [7] it seems likely that the
synergistic increases in SSAT activity in the parental
A2780 cells in our studies may likely be due to the
enhanced stability and translation of platinum drug-
induced SSAT mRNA and protein by DENSPM. SSAT
activity is post-transcriptionally regulated such that SSAT
mRNA requires a translational trigger by addition of a
natural polyamine or analog [14, 15]. The evidence pre-
sented here indicates that cells with acquired resistance to
platinum agents are deﬁcient in their ability to up-regulate
SSAT gene expression. It is important to note that lack of
SSAT induction in the resistant cells in platinum agent/
DENSPM combinations is not due to a DENSPM uptake
deﬁciency. In fact, co-treatment with either of the platinum
agents consistently increased the DENSPM levels in all
parental and resistant cells under these conditions. This
effect of the co-treatment with platinum drugs on DENS-
PM levels in cells has not been reported previously and
appears to be a potentially signiﬁcant contributing factor in
the observed synergy in induction of SSAT activity in
A2780 cells.
Fig. 5 continued
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123Whether increased DENSPM levels are a reﬂection of
an increased uptake of DENSPM or decreased metabolism
is unclear at this time as the experimental conditions
consisted of 24 h incubation in drug-free medium follow-
ing the 20-h combination treatment. DENSPM is known to
be metabolized extensively in cells [2, 3]. Our previous
studies showed that both the oxaliplatin-resistant A2780/
C10B cells and the cisplatin-resistant A2780/CP cells are
deﬁcient in platinum uptake by *50% relative to the
parental cells under very similar conditions of testing as we
described before [21, 22]. It is conceivable that the reduced
platinum levels in the resistant cells have affected the
SSAT up-regulation which appears to be the key determi-
nant in platinum drug-DENSPM combination induced
synergy at the SSAT activity level. We have previously
reported the concentration-dependent up-regulation of
SSAT gene expression for both oxaliplatin and cisplatin in
A2780 ovarian carcinoma cells [23].
A synergistic interaction of cisplatin and DENSPM has
been reported on growth inhibition in murine cell lines
L-1210 leukemia and B16F1 melanoma both in vitro and
in vivo [20]. Another study reported that pretreatment of
cells with certain polyamine analogs (DEHSPM and
DENSPM) increased the cytotoxicity of cisplatin in U-251
MG human malignant glioblastoma cells [32]. This later
study suggested that pretreatment of cells with polyamine
analogs increased the cisplatin DNA-adduct formation in
the linker regions of DNA. Although synergy was noted in
these earlier studies the rationale for combining the drugs
was not explored with respect to SSAT induction and
polyamine pool depletion in these studies. Since poly-
amines are cationic molecules that interact with the DNA
and provide stability [41] it is highly likely that when
polyamines are depleted there may be more interaction
between platinum agents and DNA. Previous studies from
our laboratory [21] and others have established that oxa-
liplatin is more potent than cisplatin [37]. Lower intracel-
lular Pt-concentrations and fewer DNA-Pt adducts are
sufﬁcient for oxaliplatin-mediated cytotoxicity compared
to cisplatin [21, 37]. It is possible that the observed supe-
riority of oxaliplatin-DENSPM combination in cell growth
inhibition in the present study may be related to potency of
DACH Pt–DNA adducts relative to CisPt–DNA adduct in
the cellular environment after polyamine pool depletion.
Marverti et al., reported that BESPM induces signiﬁ-
cantly lower levels of SSAT activity in C13* cells relative
to sensitive 2008 cells due to decreased SSAT enzyme
synthesis and high turnover in resistant cells [28]. Their
work further suggested that during selection for cisplatin
resistance a labile repressor protein was produced that
regulates SSAT gene expression [30]. Using protein syn-
thesis inhibitors, they observed enhanced transcription and
stabilization of SSAT mRNA, as well as increased SSAT
activity following BESPM treatment of C13* cells [30].
While their focus has been the polyamine analog-induced
SSAT activity in cisplatin-resistant cells, it is possible that
the highly curtailed SSAT gene expression in response to
the corresponding platinum drugs in oxaliplatin and cis-
platin-resistant cells in our study may be mediated through
similar mechanisms, in addition to the effect of reduced
platinum levels.
In conclusion, the studies presented here indicate that
the synergy displayed by platinum drug/DENSPM com-
binations in inhibition of cell growth is a blend of a
multitude of events. First, the platinum agents by them-
selves are potent inducers of SSAT mRNA in parental
cells. Co-treatment with platinum agents increases the
cellular levels of DENSPM which in turn facilitate
increased translation and stability of SSAT protein and
depletion of polyamine pools. In the cellular environment
with decreased polyamine pools, Pt–DNA adducts may be
more frequent. Fewer DACH Pt–DNA adducts being
more cytotoxic than cisplatin–DNA adducts, oxaliplatin/
DENSPM combination translates into better synergy in
cell growth inhibition than cisplatin/DENSPM combina-
tion. The curtailed induction of SSAT gene expression in
platinum resistance may be related at least partly to the
defective platinum uptake in resistant cells. Further
studies to deﬁne the molecular mechanisms behind plat-
inum drug/DENSPM synergy will pave the way for
realization of the full translational potential of these
drugs.
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